SEBI’s IGP Review 2026: What It Could Mean for Startups and Private Market Investors

 A promising startup may have strong technology and investor backing. But what happens when it needs a route to public-market capital?

India’s startup ecosystem has expanded beyond consumer technology, e-commerce and financial technology.

Businesses are emerging in deep technology, biotechnology, semiconductor design, space technology and other research-intensive industries.

These companies can have very different financial characteristics from conventional businesses.

A biotechnology company may spend several years developing products before generating meaningful commercial revenue. A semiconductor technology business may require substantial capital for research, development and testing before it reaches commercial scale.

For such enterprises, conventional public-market listing requirements may not always align neatly with their development cycles.

Recognising this challenge, the Securities and Exchange Board of India (SEBI) announced a review of its Innovators Growth Platform (IGP) framework on 4 November 2026.

The review could have implications for innovation-led companies seeking capital and investors exploring opportunities in private equity and unlisted businesses.

But one distinction is essential.

SEBI has initiated a regulatory review. It has not announced that the listing requirements under examination have already been relaxed.

For investors, the development is an opportunity to understand how companies move from private ownership towards public-market participation, and why a listing opportunity alone does not guarantee an attractive investment return.

What Happened? SEBI Constituted a Working Group to Review the IGP

On 4 November 2026, SEBI announced a working group to undertake a comprehensive review of the Innovators Growth Platform framework under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The working group will examine whether existing rules remain appropriate for innovation-led businesses, particularly those with extended research periods, intellectual-property-driven operations or limited early-stage revenue.

The review covers listing eligibility, investor participation, fundraising, pricing, disclosures, corporate governance and migration to the main board.

SEBI’s objective is to assess whether access to capital markets can be improved while maintaining investor protection.

1. What Is SEBI’s Innovators Growth Platform?

The Innovators Growth Platform is a specialised capital-market listing framework intended for eligible innovation-led companies.

It provides an alternative route for certain businesses that may not meet conventional main-board IPO eligibility requirements.

The IGP operates within SEBI’s securities-issuance and disclosure framework, with specific conditions relating to eligible companies, investors, fundraising and continued listing.

It is not simply another name for unlisted equity.

An unlisted company is generally not publicly traded on a recognised exchange, whereas securities admitted to trading on the IGP operate within a regulated listing framework.

This distinction matters for investors evaluating investment access, disclosures and liquidity.

2. Why Is SEBI Reviewing the IGP in 2026?

Innovation-led businesses often face long development periods before achieving commercial scale.

A company developing biotechnology treatments, for example, may require funding for research, trials and regulatory approvals well before substantial product revenue becomes available.

Similarly, companies working in advanced engineering or semiconductor technology may require several rounds of funding to develop commercially viable products.

Traditional valuation measures such as current profits or earnings multiples may be less useful for these businesses during their earlier stages.

SEBI’s review aims to examine whether the IGP framework adequately accommodates these different business models.

The regulator is also considering whether the platform’s existing requirements remain effective in encouraging appropriate market participation.

3. Which Areas Are Under Review?

The working group’s mandate covers several important aspects of the IGP.

The review also includes comparisons with international frameworks and consideration of possible implementation measures.

These areas are being examined, and the eventual recommendations may differ from the current framework.

4. Why Does This Matter for Private Equity Investors?

Private equity investments often involve acquiring ownership in businesses before they become publicly listed.

Investors may hold these interests for several years while the companies develop products, expand operations or improve profitability.

An eventual listing can be one possible exit route.

If the IGP framework becomes more accessible to suitable innovation-led companies, it could expand the range of public-market financing pathways available to them.

However, a potential regulatory pathway is not the same as an assured exit.

Investors must still consider the company’s fundamentals, entry valuation, shareholder rights and the conditions that would apply to any eventual listing.

A broader listing framework may create possibilities, but investment returns continue to depend on the business and the price paid.

5. How Could the Review Affect Startup Founders?

For founders, access to capital is not only about obtaining funding. It is also about choosing an appropriate financing structure.

Equity funding may support development without creating conventional scheduled debt repayments, but it can dilute existing shareholders.

Debt may preserve ownership but introduces repayment obligations and may be difficult to obtain when commercial cash flows remain uncertain.

Public-market access offers another possible financing route, subject to regulatory and market conditions.

For research-stage companies, the challenge is communicating value when commercialisation is still developing.

Founders should continue preparing audited financial information where applicable, business plans, ownership records, governance arrangements and meaningful disclosures.

A review of listing rules should not be treated as a reason to postpone financial discipline.

6. What Makes Pre-Revenue Companies Difficult to Value?

A company that has not yet generated meaningful revenue may still own valuable technology, intellectual property or scientific capabilities.

However, estimating its value involves significant assumptions.

Investors may need to consider development milestones, technical feasibility, intellectual-property rights, commercialisation prospects, future funding requirements and potential competition.

Traditional ratios such as price-to-earnings may not be meaningful where profits are absent.

Valuation assessments may therefore rely more heavily on scenario analysis, comparable transactions and expected future cash flows.

These methods involve uncertainty.

A successful technology does not automatically result in a commercially successful company, and a promising business does not automatically justify every valuation.

7. Could a Listing Improve Liquidity for Existing Shareholders?

A regulated listing may provide access to a wider pool of eligible buyers and sellers.

It can also introduce more structured price discovery and ongoing disclosure requirements.

However, IGP liquidity should not be assumed to be equivalent to liquidity in an actively traded main-board stock.

Trading activity, investor eligibility and applicable market mechanisms can affect the ability to sell shares.

Pre-existing shareholders may also face applicable transfer or lock-in restrictions.

Investors should therefore avoid using a future IGP listing as a guaranteed liquidity date.

8. Does the Review Change Existing Unlisted Share Investments?

The announcement does not automatically alter the rights, valuation or trading status of shares already held in unlisted companies.

Existing shareholders remain subject to the applicable company’s documents, securities laws and transfer conditions.

Nor does it automatically make every private company eligible for an IGP listing.

The working group must first examine the framework and make recommendations.

Any future regulatory changes would depend on SEBI’s subsequent decisions and the applicable implementation process.

For investors, the sensible response is to understand the development without treating it as immediate confirmation of a listing opportunity.

9. What Should Investors Review Before Buying Unlisted Shares?

For investors considering innovation-led businesses, fundamental due diligence remains essential.

A useful review includes the quality of management, the company’s capital structure, ownership of intellectual property, cash requirements and the likelihood of future dilution.

Investors should also assess the offered share price against realistic business assumptions.

Where the investment thesis depends heavily on a future IPO or IGP listing, it is important to test a scenario in which that listing takes longer than expected or does not occur.

A company’s ability to raise additional private capital can be relevant, but future fundraising is not assured.

The investment decision should stand on the company’s financial and commercial prospects rather than a presumed regulatory outcome.

10. What Are the Key Risks?

Innovation-led and early-stage businesses can face significant uncertainty.

Technology development may take longer than planned. Products may fail to achieve commercial acceptance. Funding requirements may increase, and subsequent financing rounds may dilute existing shareholders.

Valuations can also be difficult to establish when historical financial information is limited.

In addition, regulatory requirements and market conditions can change before a company becomes eligible for a public-market listing.

A review of listing regulations does not eliminate these risks.

Investors should evaluate the potential for loss of capital and prolonged illiquidity before committing funds.

What Should HNIs and Private Market Investors Monitor?

Investors following the IGP review should focus on five questions:

1. What changes, if any, does SEBI ultimately approve for listing eligibility?

2. How will investor participation and investment requirements be defined?

3. What disclosures will innovation-led companies need to provide?

4. What trading and liquidity arrangements will apply after listing?

5. How will eligible companies migrate from the IGP to the main board?

The answers will become clearer only as the review advances and any subsequent regulatory measures are issued.

Ranjit Jha’s Perspective — Draft for Approval

Proposed editorial perspective for Ranjit M. Jha, MD & CEO, Rurash Financials. Approval required before attribution.

India’s innovation ecosystem increasingly includes businesses that require substantial research investment and longer development cycles before achieving commercial scale.

SEBI’s decision to review the Innovators Growth Platform reflects the need to assess whether existing capital-market structures remain appropriate for these enterprises.

For private-market investors, a possible expansion of listing pathways is worth monitoring. However, greater access to capital markets should not be confused with lower investment risk.

Business quality, valuation discipline, corporate governance, liquidity and exit planning should remain central to the investment decision.

A thoughtful private equity strategy evaluates both the company’s growth potential and the terms under which investors participate.

Explore More with Rurash

At Rurash Financials, we believe private-market investing should begin with a disciplined understanding of business fundamentals, valuation, shareholder rights and liquidity.

For HNIs, family offices and experienced investors exploring unlisted equity and private equity opportunities, regulatory developments such as SEBI’s IGP review provide important market context.

Through our Private Equity and Unlisted Equity services, eligible investors can explore opportunities while considering financial objectives, investment horizons and risk capacity.

A possible new listing pathway creates interest. A sound investment decision still begins with due diligence.

Connect with Rurash Financials to discuss private-market investment opportunities.